logo
"Bigorexia" can make a gym obsession harmful but often goes unrecognized

"Bigorexia" can make a gym obsession harmful but often goes unrecognized

Yahoo06-04-2025

When Kenan was 16, he started going to the gym to get bigger. He had been bullied his entire life about his size, and once he started to see his body change in the mirror he couldn't get enough.
'I got some results and then just ran with it,' Kenan, who is using his first name only for privacy reasons, told Salon in a phone interview. 'It was like a dopamine loop from hell for the next 10 years.'
Kenan's time at the gym began to eat up the rest of his life. He would skip hanging out with friends or going on trips if it meant that he couldn't work out. He started counting every 'macro' — or macronutrient of proteins, carbohydrates and fats — that went into his body, adding thousands of calories of canola oil to his smoothies so he could put on weight. He even brought his own prepackaged meals to his cousin's wedding so he could be sure the food served there was not interfering with his regimen.
'Basically, if I did not have a great gym session where I got stronger or felt like I was improving, it ruined my entire day,' Kenan said. 'It would feel like I was a failure, like I couldn't do anything right.'
At one point, Kenan came across the term muscle dysmorphia in a bodybuilding forum and recognized his own experience. Also known as 'reverse anorexia' or 'bigorexia,' muscle dysmorphia is a pathologic preoccupation with muscularity. In the most recent version of the psychiatric manual used to classify mental illness, it is listed as a specific type of body dysmorphia rather than its own diagnosis, although it also shares some characteristics found in eating disorders.
'The goal of exercise and physical activity is to improve your life and make you feel happier and healthier,' said Dr. Jason Nagata, an adolescent medicine specialist at the University of California, San Francisco who has studied muscle dysmorphia. 'But for these individuals, it becomes a burden and an obsession that they cannot stop thinking about.'
Muscle dysmorphia was first classified in 1997 as an "underrecognized" condition that likely afflicted 'substantial numbers of Americans.' Although it has recently grown in awareness and some bodybuilders have spoken out about it, relatively little research has been conducted to better understand it since it was first introduced, said Dr. Kyle T. Ganson, a social work professor at the University of Toronto who also studies muscle dysmorphia.
That's in part because there are no questions specific to muscle dysmorphia on national surveys that are typically used to estimate a condition's prevalence in the population. And most of the studies examining muscle dysmorphia are small and limited.
Yet muscle dysmorphia has been shown to increase a person's risk for depression, anxiety, and suicidality. People with muscle dysmorphia are more likely to have experienced a traumatic event than the general population. And people with muscle dysmorphia are also more likely to use supplements and steroids, which carry their own health risks.
Kenan experienced overuse injuries in his elbows, knees and back. One time, he nearly broke a rib on his lifting belt, but he kept going back to the gym, even though it hurt to breathe.'There was a running calendar my friends would keep about how long it would take me to get injured because I was pushing it too hard,' Kenan said.
In one study Ganson published earlier this year, he estimated that 2.8% of boys and men in the U.S. and Canada could meet criteria for muscle dysmorphia. It is more common in people identifying as men and in certain populations, like bodybuilders. However, these numbers are likely underestimated. For example, in another 2019 study Ganson conducted, 22% of males and 5% of females reported disordered eating behaviors related to muscularity.
'We need more research on clinical samples, how to treat these individuals, and what barriers there are to treatment,' Ganson told Salon in a phone interview. 'I think a lot of that is still somewhat in its infancy.'
Eating disorders are themselves understudied within the mental health field, where conditions like anorexia have incorrectly been stereotyped as only affecting teenage girls. Efforts to understand how social media perpetuates unrealistic body standards that affect mental health have also largely been focused largely on girls. Yet the increasing prevalence of muscle dysmorphia suggests it is having an effect on everyone.
'Both muscle dysmorphia and anorexia can be viewed as disorders where an individual has internalized these messages about idealized masculinity or femininity in such an extreme way that it is causing distress and dysfunction to the other parts of their lives,' said Linda Lin, a psychologist at Emmanuel College who has studied muscle dysmorphia.
More recent research has demonstrated that one in three eating disorders occurs among boys, and gender diverse people experience them at even higher rates. Yet muscle dysmorphia falls in a unique position where exercise and strength training are considered healthy habits in society, and as such may not be seen as problematic — even when they are pushed to the extreme.
'In general, people with eating disorders like other mental health conditions face stigma, and people don't want to out themselves for having a disorder,' Nagata told Salon in a phone interview. 'I think for boys, there is sort of a double stigma.'
Society supports the idea that muscularity equals masculinity, and the media portrays certain standards for what the male body 'should' look like. In addition to male bodies getting larger and larger in superhero movies, one 1999 study found that even the size and muscularity of toy action figures children play with growing up have been expanding over time. In our consumerist society, 'more' is often conflated with better.
'When I went to the gym, my trainer used to 'boo' thin people,' said Giuseppe Magistrale, a psychologist who founded an online treatment program for eating disorders called Lilac. 'In the gym, it is super normalized. There is a culture.'
With the proliferation of social media, these unrealistic expectations of body image have become even more prolific, adding to the pressures men face to conform to them. In one 2020 study, Instagram posts that represented bigger muscles got more likes. Another published in September in the journal Body Image found the use of filters was associated with muscle dysmorphia symptoms.
'Previous generations didn't really have that, versus now if you look at movies and TV and all of these things, all of a sudden guys have this intense pressure to look a certain way,' Kenan said. 'That pressure was really mounting.'
All of this ultimately delays the time that it takes people with muscle dysmorphia to seek treatment. Like with eating disorders, many people with muscle dysmorphia may end up originally seeking help for something else before the topic of dysmorphia arises. Kenan, for example, ultimately decided to seek help from a therapist after his relationship fell apart.
Treatments for people with muscle dysmorphia will vary based on the individual and provider, in part because there have been no randomized control trials to test which therapies work best. (One clinical trial testing cognitive behavioral therapy is currently underway in Turkey.) Some are pushing for muscle dysmorphia to be classified as its own disorder, so that it can be better measured and studied.
'The creation of a diagnosis is very important because it validates the problem,' Magistrale said. 'In male culture and gym culture, it is still [seen as] a non-existent disorder, so at the cultural level, we have a lot of work to do.'
Sometimes, treating muscle dysmorphia may involve an interdisciplinary team including a mental health, medical, and nutrition provider, Nagata said. Ultimately, treatment for muscle dysmorphia is about healing the relationship patients have with their body, exercise, and food, said Dr. Lindsey Landgrebe, a licensed sport psychologist who specializes in working with athletes in her private practice.
'I think it's about first understanding their drive for being bigger and more muscular … and then working to build other ways of coping with whatever the underlying distress is,' Landgrebe told Salon in a phone call. 'It's also a matter of expanding how they see themselves so they can understand their value is more than just their appearance.'
Kenan was able to trace the origins of his muscle dysmorphia back to getting bullied as a child for his size.
'I figured there were two ways to deal with it: either own it, or change it,' he said. 'I think that is what started it for me.'
These days, he is going to the gym less and doesn't restrict his meals. He has been able to redirect the energy he was putting toward the gym into personal development, relationships and his career, he said.
'I took that tenacity I had at the gym and put it toward reading books and self-educating myself based on what my therapists have suggested,' Kenan said. 'I kind of just replaced the hyperobsession I had at the gym with [other parts of] life and found balance.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NEWT GINGRICH: Pay less, know more — Trump is slashing red tape and lowering your healthcare costs
NEWT GINGRICH: Pay less, know more — Trump is slashing red tape and lowering your healthcare costs

Fox News

time11 minutes ago

  • Fox News

NEWT GINGRICH: Pay less, know more — Trump is slashing red tape and lowering your healthcare costs

One of the boldest and most consistent themes in President Donald J. Trump's healthcare agenda is his determination to reduce the role and power of middlemen. From insurance companies to pharmacy benefit managers (PBMs) – and even hospitals –these intermediaries profit from the inefficiencies of our bloated health system. The result is higher costs for American families. As I explain in my new book, "Trump's Triumph: America's Greatest Comeback," the U.S. healthcare system isn't expensive just because care is costly. It's expensive because the system is complex – by design. The third-party payment structure, whether public or private, adds layers of bureaucracy. This opens the door for middlemen to offer supposed solutions that serve their own bottom lines – not patients. It's a vicious cycle: more rules lead to more middlemen, which lead to even more rules, red tape, and rising costs. President Trump understood this – and he took action. In his first term, he issued a groundbreaking executive order on price transparency. For the first time, hospitals were required to disclose the real cost of procedures, enabling patients to compare prices before receiving care. While the Biden administration weakened enforcement, Trump doubled down in his second term with an even stronger push for what he called "radical transparency." Radical transparency is the antidote to healthcare's worst inefficiencies. When patients and employers can see wide price differences for the same procedures – even within the same hospital system – the games played behind the scenes get exposed. These inflated prices often have little to do with quality and everything to do with how well insurers negotiate – or how many middlemen take a cut. The same is true for prescription drugs. PBMs – giant corporations that control which drugs are covered and at what cost – use their market power to inflate prices. Three PBMs control 80 percent of the market. They're often subsidiaries of major insurers, forming vertically integrated monopolies. New data from the Pacific Research Institute shows that most PBMs skim more money off high-cost prescriptions than European countries charge. It's no wonder Americans are paying more. Hospitals play a role as well. Many exploit a well-intentioned federal program known as 340B, which allows them to purchase drugs at steep discounts. Instead of passing the savings to patients, they bill insurers full price and pocket the difference. The program was meant to expand care for low-income patients, but there's little oversight to ensure this happens. President Trump's recent executive order on drug pricing targets this broken system. By creating a pathway for manufacturers to sell directly to patients, health plans, pharmacies, and clinics – without the markup – he's offering a way to bypass the middlemen. This isn't theory – it's already working. When insulin makers launched direct-to-consumer programs, they sold the same drug at one-fourth the price patients were paying through insurance – while still making a profit. That's the power of real market competition – without a single government price control. This stands in sharp contrast to the Left's top-down vision. Whether it's price controls, centralized purchasing, or government-run insurance, the left's answer is always more bureaucracy. But more bureaucracy means more complexity – and more room for middlemen to thrive. Perhaps the most visionary part of President Trump's health care agenda is his call to Make America Healthy Again. For decades, we've operated a "sick care" system focused on treating illness after it strikes. Trump's approach is different. It emphasizes prevention, lifestyle, and personal responsibility – turning Americans from passive recipients into active participants in their own health. In this model, the government's role isn't to run the system but to create an environment in which patients and doctors can lead – with access to better tools, more transparency, and useful information. That means clearer labeling for ultra-processed foods, ensuring gold standard scientific data free of conflicts of interest, and addressing environmental factors that contribute to chronic disease. These kinds of structural reforms empower people to make informed choices and live healthier lives – without mandates or micromanagement. It's a model that eliminates the ultimate middleman: the system itself. President Trump's leadership has laid the groundwork for a transparent, patient-centered, free-market healthcare system. But the job isn't done. Congress should join him in continuing this fight – not just to lower costs, but to restore power to the American people. America deserves a healthcare system that benefits Americans – not industry middlemen.

A plan to preserve U.S. science leadership
A plan to preserve U.S. science leadership

Politico

timean hour ago

  • Politico

A plan to preserve U.S. science leadership

PROBLEM SOLVERS National Academy of Sciences President Marcia McNutt made a plea to the nation's science research community during her second annual State of the Science address in Washington on Tuesday: Course-correct or lose to China. We're in the midst of a 'radical new experiment,' McNutt explained, in which the U.S., by pursuing budget cuts, canceling grants and adopting restrictive research policies, serves as the treatment group, while China is the control. Unforced errors made during the pandemic eroded many Americans' trust in science. But there's still at least one point of agreement: 'Everyone, whether it's scientists or nonscientists alike, wants U.S. science to be the world leader.' To remain a world leader in science innovation, McNutt laid out a plan. Among her key suggestions: — Build on a culture of innovation. McNutt worries that budget cuts will fuel overly conservative project selection and lead to less funding for high-risk, high-reward research. To course-correct, the U.S. should do a data-informed analysis of various peer-review approaches to ensure 'truly innovative' proposals succeed. — Create a national research strategy. 'No sensible business person would attempt to run a multibillion-dollar enterprise without a strategy, and yet that is exactly what we are doing with our research enterprise,' she said. In McNutt's view, relying on Congress to tinker with budgets isn't a strategy. Countries like China, Germany, Japan and Norway maximize research and development investment through strategic planning, primarily with apolitical non-government organizations, McNutt added. — Improve science education. The U.S. is already failing to produce enough STEM students to fill available jobs in science. The Trump administration's clampdown on visas will make it even more difficult for immigrants to fill those jobs. Beyond filling jobs, having science-literate lawyers, politicians and workers in manufacturing and transportation strengthens the nation's scientific enterprise. — Don't retreat from international collaboration. Some cutting-edge research facilities require resources from more than one nation. And when international students return home, their U.S. connections drive further international collaboration. 'We squander opportunities by not taking advantage of the fact that international colleagues want to work with us, and we only disadvantage ourselves,' McNutt said. — Cut red tape. Regulations divert time and money away from science, McNutt argues. And since the Trump administration has prioritized reducing regulations, McNutt hopes that push extends to research regulations. Still, in the Department of Government Efficiency era, that's not a given. 'I worry that the emphasis right now on waste, fraud and abuse only leads to more regulations, as everyone is assumed guilty until proven innocent.' The elephant in the room: The National Academy of Sciences is 'preparing for a fairly radical downsizing' amid the Trump administration's science cuts, McNutt told Stat News last month. A budget shortfall of roughly $40 million resulting from terminated contracts means the organization might have to lay off 250 employees in addition to the 50 members of the 1,000-person staff who have already been let go. WELCOME TO FUTURE PULSE This is where we explore the ideas and innovators shaping health care. Pope Leo XIV wants to stop artificial intelligence from playing God. Like his namesake, Pope Leo XIII, who promoted workers' rights during the industrial revolution, the new pope is positioning himself as a guardian in the face of unchecked modern technology, POLITICO's Hannah Roberts reports. Share any thoughts, news, tips and feedback with Danny Nguyen at dnguyen@ Carmen Paun at cpaun@ Ruth Reader at rreader@ or Erin Schumaker at eschumaker@ Want to share a tip securely? Message us on Signal: Dannyn516.70, CarmenP.82, RuthReader.02 or ErinSchumaker.01. WORLDVIEW England's National Health Service has launched an internal review into an artificial intelligence model being trained on data from 57 million patients in England, our POLITICO colleagues across the pond scooped. Called Foresight, the generative AI model was touted as a 'world-first pilot project' to pinpoint high-risk patient groups and facilitate early interventions. Foresight was trained on de-identified data from millions of people in England, including a large-scale dataset called the General Practice Extraction Service Data for Pandemic Planning and Research. But doctors have serious misgivings about the model being trained on their patient records without proper authorization. What the docs say: Last month, representatives from the British Medical Association and Royal College of General Practitioners wrote to Ming Tang, chief data and analytics officer at NHS England, expressing 'serious concerns about the lawfulness of the data use and the apparent absence of strict governance arrangements,' according to an email seen by POLITICO. The bone of contention is whether NHSE took patient data solely intended for Covid-19 research and incorporated it into an all-purpose AI model. NHSE's guidelines state that applications for accessing patient data must undergo additional review by its Professional Advisory Group. The advisory group approved the British Heart Foundation consortium's use of the primary care data specifically for Covid-related research during the pandemic but was never consulted about large language model training. The official line: An NHSE spokesperson said: 'Maintaining patient privacy is central to this project, and we are grateful to the Joint GP IT Committee for raising its concerns and meeting with us to discuss the strict governance and controls in place to ensure patients' data remains secure.' What's next: The Joint GP IT Committee, which advises on IT matters related to general practice medicine, plans to write to the Information Commissioner directly, a person familiar with the situation told POLITICO. In addition to demanding that the British Medical Association be called as a witness to the Information Commissioner, the joint commission wants 'explicit governance' over future uses of AI and an undertaking that any future emergency measures permitting the use of general practitioners' data contain a sunset clause if doctors haven't been consulted, the person said.

Two patients faced chemo. The one survivor demanded a test to see if it was safe
Two patients faced chemo. The one survivor demanded a test to see if it was safe

Miami Herald

timean hour ago

  • Miami Herald

Two patients faced chemo. The one survivor demanded a test to see if it was safe

JoEllen Zembruski-Ruple, while in the care of New York City's renowned Memorial Sloan Kettering Cancer Center, swallowed the first three chemotherapy pills to treat her squamous cell carcinoma on Jan. 29, her family members said. They didn't realize the drug could kill her. Six days later, Zembruski-Ruple went to Sloan Kettering's urgent care department to treat sores in her mouth and swelling around her eyes. The hospital diagnosed oral yeast infection and sent her home, her sister and partner said. Two days later, they said, she returned in agony — with severe diarrhea and vomiting — and was admitted. 'Enzyme deficiency,' Zembruski-Ruple texted a friend. The 65-year-old, a patient advocate who had worked for the National Multiple Sclerosis Society and other groups, would never go home. Covered in bruises and unable to swallow or talk, she eventually entered hospice care and died March 25 from the very drug that was supposed to extend her life, said her longtime partner, Richard Khavkine. Zembruski-Ruple was deficient in the enzyme that metabolizes capecitabine, the chemotherapy drug she took, said Khavkine and Susan Zembruski, one of her sisters. Zembruski-Ruple was among about 1,300 Americans each year who die from the toxic effects of that pill or its cousin, the IV drug fluorouracil known as 5-FU. Doctors can test for the deficiency — and then either switch drugs or lower the dosage if patients have a genetic variant that carries risk. The FDA approved an antidote in 2015, but it's expensive and must be administered within four days of the first chemotherapy treatment. Newer cancer drugs sometimes include a companion diagnostic to determine whether a drug works with an individual patient's genetics. But 5-FU went on the market in 1962 and sells for about $17 a dose; producers of its generic aren't seeking approval for toxicity tests, which typically cost hundreds of dollars. Doctors have only gradually understood which gene variants are dangerous in which patients, and how to deal with them, said Alan Venook, a colorectal and liver cancer specialist at the University of California-San Francisco. By the time Zembruski-Ruple's doctors told her she had the deficiency, she had been on the drug for eight days, said Khavkine, who watched over his partner with her sister throughout the seven-week ordeal. Khavkine said he 'would have asked for the test' if he had known about it, but added 'nobody told us about the possibility of this deficiency.' Zembruski-Ruple's sister also said she wasn't warned about the fatal risks of the chemo, or told about the test. 'They never said why they didn't test her,' Zembruski said. 'If the test existed, they should have said there is a test. If they said, 'Insurance won't cover it,' I would have said, 'Here's my credit card.' We should have known about it.' Guidance moves at a glacial pace Despite growing awareness of the deficiency, and an advocacy group made up of grieving friends and relatives who push for routine testing of all patients before they take the drug, the medical establishment has moved slowly. A panel of the National Comprehensive Cancer Network, or NCCN — specialists from Sloan Kettering and other top research centers — until recently did not recommend testing, and the FDA does not require it. In response to a query from KFF Health News about its policy, Sloan Kettering spokesperson Courtney Nowak said the hospital treats patients 'in accordance with NCCN guidelines.' She said the hospital would not discuss a patient's care. On Jan. 24, the FDA issued a warning about the enzyme deficiency in which it urged health care providers to 'inform patients prior to treatment' about the risks of taking 5-FU and capecitabine. On March 31 — six days after Zembruski-Ruple's death — the network's expert panel for most gastrointestinal cancers took a first step toward recommending testing for the deficiency. Worried that President Donald Trump's FDA might do nothing, Venook said, the panel — whose guidance shapes the practices of oncologists and health insurers — recommended that doctors consider testing before dosing patients with 5-FU or capecitabine. However, its guidance stated that 'no specific test is recommended at this time,' citing a lack of data to 'inform dose adjustments.' Sloan Kettering 'will consider this guidance in developing personalized treatment plans for each patient,' Nowak told KFF Health News. The new NCCN guidance was 'not the blanket recommendation we were working toward, but it is a major step toward our ultimate goal,' said Kerin Milesky, a public health official in Brewster, Massachusetts, who's part of an advocacy group for testing. Her husband, Larry, died two years ago at age 73 after a single treatment of capecitabine. European drug regulators began urging oncologists to test patients for deficiency in May 2020. Patients with potentially risky genetics are started on a half-dose of the cancer drug. If they suffer no major toxicity, the dose is increased. A lifesaving ultimatum? Emily Alimonti, a 42-year-old biotech salesperson in upstate New York, chose that path before starting capecitabine treatment in December. She said her doctors — including an oncologist at Sloan Kettering — told her they didn't do deficiency testing, but Alimonti insisted. 'Nope,' she said. 'I'm not starting it until I get the test back.' The test showed that Alimonti had a copy of a risky gene variant, so doctors gave her a lower dose of the drug. Even that has been hard to tolerate; she's had to skip doses because of low white blood cell counts, Alimonti said. She still doesn't know whether her insurer will cover the test. Around 300,000 people are treated with 5-FU or capecitabine in the United States each year, but its toxicity could well have prevented FDA approval were it up for approval today. Short of withdrawing a drug, however, U.S. regulators have little power to manage its use. And 5-FU and capecitabine are still powerful tools against many cancers. At a January workshop that included FDA officials and cancer specialists, Venook, the NCCN panel's co-chair, asked whether it was reasonable to recommend that doctors obtain a genetic test 'without saying what to do with the result.' But Richard Pazdur, the FDA's top cancer expert, said it was time to end the debate and commence testing, even if the results could be ambiguous. 'If you don't have the information, how do you have counseling?' he asked. Two months later, Venook's panel changed course. The price of tests has fallen below $300 and results can be returned as soon as three days, Venook said. Doubts about the FDA's ability to further confront the issue spurred the panel's change of heart, he said. 'I don't know if FDA is going to exist tomorrow,' Venook told KFF Health News. 'They're taking a wrecking ball to common sense, and that's one of the reasons we felt we had to go forward.' On May 20, the FDA posted a Federal Register notice seeking public input on the issue, a move that suggested it was considering further action. Venook said he often tests his own patients, but the results can be fuzzy. If the test finds two copies of certain dangerous gene variants in a patient, he avoids using the drug. But such cases are rare — and Zembruski-Ruple was one of them, according to her sister and Khavkine. Many more patients have a single copy of a suspect gene, an ambiguous result that requires clinical judgment to assess, Venook said. A full-gene scan would provide more information but adds expense and time, and even then the answer may be murky, Venook said. He worries that starting patients on lower doses could mean fewer cures, especially for newly diagnosed colon cancer patients. Power should rest with patients Scott Kapoor, a Toronto-area emergency room physician whose brother Anil, a much-loved urologist and surgeon, died of 5-FU toxicity at age 58 in 2023, views Venook's arguments as medical paternalism. Patients should decide whether to test and what to do with the results, he said. 'What's better — don't tell the patient about the test, don't test them, potentially kill them in 20 days?' he said. 'Or tell them about the testing while warning that potentially the cancer will kill them in a year?' 'People say oncologists don't know what to do with the information,' said Karen Merritt, whose mother died after an infusion of 5-FU in 2014. 'Well, I'm not a doctor, but I can understand the Mayo Clinic report on it.' The Mayo Clinic recommends starting patients on half a dose if they have one suspect gene variant. And 'the vast majority of patients will be able to start treatment without delays,' Daniel Hertz, a clinical pharmacologist from the University of Michigan, said at the January meeting. Some hospitals began testing after patients died because of the deficiency, said Lindsay Murray, of Andover, Massachusetts, who has advocated for widespread testing since her mother was treated with capecitabine and died in 2021. In some cases, Venook said, relatives of dead patients have sued hospitals, leading to settlements. Kapoor said his brother — like many patients of non-European origin — had a gene variant that hasn't been widely studied and isn't included in most tests. But a full-gene scan would have detected it, Kapoor said, and such scans can also be done for a few hundred dollars. The cancer network panel's changed language is disappointing, he said, though 'better than nothing.' In video tributes to Zembruski-Ruple, her friends, colleagues, and clients remembered her as kind, helpful, and engaging. 'JoEllen was beautiful both inside and out,' said Barbara McKeon, a former colleague at the MS Society. 'She was funny, creative, had a great sense of style.' 'JoEllen had this balance of classy and playful misbehavior,' psychotherapist Anastatia Fabris said. 'My beautiful, vibrant, funny, and loving friend JoEllen.' KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store